🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

22 recruiting trials

for Newly Diagnosed Multiple Myeloma (NDMM)

Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma NCT07891923Phase 22 sites📍 Navi Mumbai📍 Navi Mumbai Tata Memorial Centre · Tests: Daratumumab (Intravenously) with VRd (Bortezomib, Lenalidomide, and Dexamethasone) A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment NCT05828511Phase 1, Phase 232 sites📍 Los Angeles📍 Orange📍 Denver Regeneron Pharmaceuticals · Tests: Linvoseltamab Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma NCT07652138Phase 11 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: BCMA/CD19-targeted allogeneic CAR-T Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients NCT06918002Phase 369 sites📍 Brussels📍 Brussels📍 Charleroi Intergroupe Francophone du Myelome · Tests: Elranatamab, Lenalidomide (Revlimid®), Daratumumab SC (Darzalex), Autologous Stem Cell Transplantation, Bortezomib (Vel… Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM NCT06099912n/a1 site📍 Changchun FengYan Jin Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma NCT06974786Phase 211 sites📍 Birmingham📍 Denver📍 Iowa City SCRI Development Innovations, LLC · Tests: Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients NCT06682156n/a1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Carfilzomib Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients NCT07087964n/a4 sites📍 Antwerp📍 Ghent📍 Leuven Universiteit Antwerpen Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients NCT07296627n/a1 site📍 Beijing Peking University People's Hospital Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT NCT07764978Phase 3124 sites📍 Gilbert📍 Phoenix📍 Tucson AstraZeneca · Tests: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide NCT05558319Phase 368 sites📍 Alcalá de Henares📍 Pozuelo de Alarcón📍 Pamplona PETHEMA Foundation · Tests: Bortezomib, Isatuximab, Iberdomide, Lenalidomide, Dexamethasone Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. NCT07107529Phase 229 sites📍 Ascoli Piceno📍 Bari📍 Bergamo European Myeloma Network B.V. · Tests: Teclistamab, Talquetamab, Daratumumab Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse NCT06910124Phase 21 site📍 Miami Dickran Kazandjian, MD · Tests: Linvoseltamab, Lenalidomide D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM NCT07624513Phase 33 sites📍 Boston📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan Horizon Two: HR NDMM (MMRC-100) NCT07053436Phase 212 sites📍 Duarte📍 Atlanta📍 Chicago Multiple Myeloma Research Consortium · Tests: Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). NCT07735637Phase 3114 sites📍 Gilbert📍 Goodyear📍 Phoenix AstraZeneca · Tests: AZD0120, Cyclophosphamide, Fludarabine, Melphalan (part of ASCT), Lenalidomide A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) NCT06679101Phase 3181 sites📍 Mobile📍 Phoenix📍 Beverly Hills GlaxoSmithKline · Tests: Belantamab mafodotin, Lenalidomide, Dexamethasone, Daratumumab Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment NCT05561387Phase 3397 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned NCT07665450Phase 330 sites📍 Nantes📍 Pierre-Bénite📍 Athens Janssen Research & Development, LLC · Tests: Ramantamig, Daratumumab, Lenalidomide, Bortezomib, Dexamethasone Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients NCT07663253n/a13 sites📍 Beijing📍 Guangzhou📍 Shenzhen Shanghai Zhongshan Hospital · Tests: Isatuximab, Bortezomib, Lenalidomide, Dexamethasone 18F-Fluciclovine PET/CT in Multiple Myeloma NCT06103838Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: 18F-fluciclovine injection, 18F-FDG PET/CT KPD Consolidation After ASCT in NDMM Patients NCT06879379Phase 2, Phase 33 sites📍 Beijing📍 Beijing📍 Shanghai Peking University People's Hospital · Tests: KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy